Ito Y, Yano S, Watanabe K, Yamanaka E, Aimi N, Sakai S
Department of Drug Evaluation and Toxicological Sciences, Faculty of Pharmaceutical Sciences, Chiba University, Japan.
Chem Pharm Bull (Tokyo). 1990 Jun;38(6):1702-6. doi: 10.1248/cpb.38.1702.
We investigated the selectivities and structure requirements for alpha-1 and alpha-2 adrenoceptor blocking activities of yohimbine (YO) and its 12 related analogs, such as beta-yohimbine (beta-YO), dihydrocorynantheine (DHC) and (-)indoloquinolizidine ((-)IQ). The affinity of YO analogs to alpha-adrenoceptor was assessed by measuring their blockade of pressor responses to epinephrine in pithed rats. Among YO structure groups, the potency order was YO greater than DHC = beta-YO greater than geissoschizine methylether greater than 14 beta-hydroxy YO greater than 14 beta-benzoyloxy YO (inactive). (-)IQ was slightly less potent than YO, but much stronger than (+)IQ. Among (+/-)IQ structure groups, the potency order was (+/-)IQ greater than (+/-)1,12b-trans-1-hydroxy IQ much greater than (+/-)1,12b-cis-1-hydroxy IQ (inactive). (+/-)Borrerine was active, but (+/-)desmethylborrerine was inactive. The alpha-1 blocking activities of the four compounds YO, beta-YO, DHC and (-)IQ, were assessed in experiments of pressor responses to methoxamine in pithed rats and contractile responses to methoxamine in the rat vas deferens. The potency order was (-)IQ greater than YO greater than DHC greater than beta-YO. Furthermore, the alpha-2 blocking activities of the four analogs were assessed in experiments of pressor responses to clonidine and inhibition of electrically driven cardioacceleration by clonidine, in pithed rats. The potency order was YO greater than beta-YO greater than (-)IQ greater than DHC. Based on the potency ratio between alpha-1 and alpha-2 blocking activities, DHC or YO was most selective for alpha-1 or alpha-2 subtype, respectively, among the four YO analogs.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了育亨宾(YO)及其12种相关类似物(如β-育亨宾(β-YO)、二氢柯楠因(DHC)和(-)吲哚喹嗪((-)IQ))对α-1和α-2肾上腺素能受体阻断活性的选择性和结构要求。通过测量它们对去大脑大鼠肾上腺素升压反应的阻断作用,评估了YO类似物对α-肾上腺素能受体的亲和力。在YO结构组中,效力顺序为YO>DHC = β-YO>盖苏西嗪甲基醚>14β-羟基YO>14β-苯甲酰氧基YO(无活性)。(-)IQ的效力略低于YO,但比(+)IQ强得多。在(±)IQ结构组中,效力顺序为(±)IQ>(±)1,12b-反式-1-羟基IQ>>(±)1,12b-顺式-1-羟基IQ(无活性)。(±)博瑞林有活性,但(±)去甲基博瑞林无活性。在去大脑大鼠对甲氧明的升压反应实验和大鼠输精管对甲氧明的收缩反应实验中,评估了四种化合物YO、β-YO、DHC和(-)IQ的α-1阻断活性。效力顺序为(-)IQ>YO>DHC>β-YO。此外,在去大脑大鼠对可乐定的升压反应实验和可乐定对电驱动心脏加速的抑制实验中,评估了这四种类似物的α-2阻断活性。效力顺序为YO>β-YO>(-)IQ>DHC。基于α-1和α-2阻断活性之间的效力比,在四种YO类似物中,DHC或YO分别对α-1或α-2亚型最具选择性。(摘要截断于250字)